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In the last decade, a plethora of studies utilizing pharmacological, biochemical, and genetic
approaches have shown that precise translational control is required for long-lasting synap-
tic plasticity and the formation of long-term memory. Moreover, more recent studies
indicate that alterations in translational control are a common pathophysiological fea-
ture of human neurological disorders, including developmental disorders, neuropsychiatric
disorders, and neurodegenerative diseases. Finally, translational control mechanisms are
susceptible to modiﬁcation by psychoactive drugs. Taken together, these ﬁndings point to
a central role for translational control in the regulation of synaptic function and behavior.
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INTRODUCTION
The critical importance of de novo protein synthesis as a molec-
ular mechanism involved in the process of consolidating storage
of information in the brain has been shown in numerous exper-
imental systems using a variety of pharmacological and genetic
approaches (Neves et al., 2008). For instance, one of the ﬁrst
behavioral studies performed in rodents treated with the protein
synthesis inhibitor puromycin demonstrated that loss of memory
for avoidance discrimination learning was caused by blockade of
protein synthesis (Flexner et al., 1963).
Information is encoded and stored in the brain at the level of
individual synapses, which represent the “cellular unit of memo-
ries” (Hoeffer and Klann, 2010). Synapses are“plastic” in that their
physiological efﬁcacy (strength) changes and outlasts the events
that trigger them. These persistent, activity-dependent changes
in synaptic strength are triggered by de novo protein synthesis
(Klann and Sweatt, 2008). Evidence indicating that protein syn-
thesis can occur at speciﬁc synaptic sites comes from electron
microscopy studies that demonstrated the presence of polyri-
bosomes in dendrites of dentate granule neurons (Steward and
Levy, 1982; Steward and Schuman, 2001). Accordingly, electri-
cal stimulation of CA1 pyramidal cell dendrites led to the rapid
incorporation of radiolabeled amino acids into newly synthesized
proteins (Feig and Lipton, 1993). The functional role of den-
dritic protein synthesis then was demonstrated in hippocampal
slices where newly synthesized proteins were required to enhance
synaptic strength induced by brain-derived neurotrophic factor
(BDNF; Kang and Schuman, 1996). In addition, dendritic pro-
tein synthesis is necessary for long-lasting decreases in synaptic
strength induced by activation of group I metabotropic glutamate
receptors (Huber et al., 2000). These ﬁndings indicate that pro-
tein synthesis is triggered at synaptic locations and is required
for several forms of synaptic plasticity, which in turn is thought
to be essential for higher brain functions, including memory
formation.
Biochemical signaling mechanisms coordinating the process
of neuronal protein synthesis are highly regulated and can be
separated into three general phases: initiation, elongation and ter-
mination. The vast majority of the known translation regulation
occurs at the level of the initiation phase and involves the coor-
dinate activities of numerous molecular factors (Costa-Mattioli
et al., 2009a; Richter and Klann, 2009; Sossin and Lacaille, 2010).
Critical to the regulation of translation initiation is the activity of
mammalian target of rapamycin (mTOR), a kinase ubiquitously
expressed in eukaryotes (Hoeffer and Klann, 2010). In this review,
we describe molecular mechanisms that control translation initia-
tion and discuss examples of how perturbations of this regulation
are a common pathophysiological feature of human neurological
disorders.
mTOR SIGNALING PATHWAY AND TRANSLATION INITIATION
Mammalian target of rapamycin function is regulated by the activ-
ity state of several neuronal surface receptors and channels (i.e.,
TrkB,NMDAR,AMPA,D1R,D2R,mGluRs) and by diverse signal-
ing cascades activated by these receptors, including PDK1, PI3K,
Akt, and TSC1/2 (Averous and Proud, 2006; Wang and Proud,
2006). mTOR is a serine–threonine kinase and exists as one com-
ponent of protein complexes termed mTORCs (Figure 1) that
include numerous factors regulating mTOR signaling and con-
trolling the speciﬁcity for its diverse effectors targets, as well as
directing its subcellular localization (Cutler et al., 1999; Martin
and Blenis, 2002).
mTORCs are deﬁned primarily by the key scaffold proteins
interacting with mTOR, Raptor, and Rictor. mTOR, when found
in a complex with Raptor is known as mTORC1, whereas mTOR
bound to Rictor is known as mTORC2 (Beretta et al., 1996;
Kim et al., 2002; Sarbassov et al., 2004). These two complexes
are thought to participate in the regulation of diverse signal-
ing pathways that mediate different neuronal functions. Indeed,
mTORC1 is primarily involved in the regulation of cap-dependent
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FIGURE 1 | Schematic of mTOR signaling pathways. Activation of
neuronal receptors and channels (mGluRs, NMDARs, TrkB, D1Rs, and
D2Rs) leads to activation of mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2). mTORC1 activation increases some neuronal
processes (protein synthesis) while inhibiting others (autophagy). mTORC1
regulates the activity of downstream effectors involved in translation (S6K1,
4E-BP2), some of which are also directly phosphorylated via convergent
activation of the MAPK signaling pathway (S6K1, MnK, S6).
mTORC1-dependent phosphorylation of 4E-BP2 results in the association
of eIF4E with eIF4G and the formation of the active eIF4F
(eIF4E–eIF4A–eIF4G) complex. eIF4F recruits eIF4B and MnK and
promotes the binding of mRNAs to the 43S pre-initiation complex to form
the 48S initiation complex. The eIF4F complex and the poly(A) tail act
synergistically together with MnK-dependent phosphorylation of eIF4E to
stimulate cap-dependent translation initiation. The signaling pathways that
activate mTORC2 and its downstream effectors, as well as its physiological
functions are currently unknown. Black solid arrows indicate direct
phosphorylation/activation, pink double arrows represent molecular
association/dissociation and blue lines indicate inhibition.
translation initiation, whereas mTORC2 is implicated in struc-
tural modiﬁcations such as cytoskeletal rearrangements (Jacinto
and Hall, 2003; Hay and Sonenberg, 2004). Furthermore, these
two complexes have different sensitivity to rapamycin, which does
not inhibit mTOR kinase activity per se, but rather interferes with
the binding of mTOR to Raptor, thereby disrupting mTORC1 and
the phosphorylation of its substrates (Figure 1). Thus, mTORC1,
but not mTORC2, is inhibited by rapamycin (Beretta et al., 1996;
Kim et al., 2002), although prolonged treatment with rapamycin
in cultured cells may also indirectly inhibit mTORC2 (Sarbassov
et al., 2006).
Critical downstream targets of mTORC1 that are involved in
translation include the p70 ribosomal S6 kinases 1 and 2 (S6K1 and
S6K2) and the eIF4E-binding proteins (4E-BP; Klann and Dever,
2004). S6K1 is involved in the phosphorylation of the ribosomal
protein S6 (Figure 1), an essential component of the 40S ribosomal
subunit, and regulates its synthesis. The role of S6 in the regulation
of translation is not well understood. S6 is located in close proxim-
ity to mRNA- and tRNA-binding sites, and genetic deletion of S6
impairs ribosome biogenesis and cell proliferation (Volarevic et al.,
2000). S6K1 also mediates the phosphorylation of initiation factor
4B (eIF4B), which increases the catalytic activity of eIF4A (Rogers
et al., 2001b; Raught et al., 2004), an RNA helicase critical for the
translation of mRNA with complex 5′UTR secondary structures
(Rogers et al., 1999, 2001a). Furthermore, S6K1 is also involved in
translation elongation via phosphorylation of elongation factor 2
(eEF2) kinase. Phosphorylation of eEF2 kinase by S6K1 enhances
the elongation rate and presumably protein synthesis by inhibiting
its kinase activity, thereby decreasing the phosphorylation of eEF2
(Wang et al., 2001).
4E-BPs, which will be referred to from this point on as 4E-BP2
(Figure 1) because it is the predominant isoform in the mam-
malian brain (Banko et al., 2005), bind to the cap-binding protein
eIF4E and repress its interaction with eIF4G and the other factors
involved in formation of the initiation complex (Pause et al., 1994;
Haghighat et al., 1995; Fletcher et al., 1998; Poulin et al., 1998).
Thus, 4E-BP2 blocks eIF4F formation and inhibits protein synthe-
sis by competing with eIF4G for the binding of eIF4E (Figure 1).
The repressor activity of 4E-BP2 is regulated by sequential phos-
phorylation of its numerous phosphorylation sites (Bidinosti et al.,
2010). The various 4E-BP2 residues are phosphorylated by diverse
kinases in a sequential manner, with the last phosphorylation
event occurring by mTORC1 (Gingras et al., 1999, 2001). Thus,
mTORC1-dependent phosphorylation of 4E-BP2 releases eIF4E,
which in turn associates with eIF4G. The binding of eIF4E to
eIF4G and eIF4A forms the eIF4F initiation complex, which also
recruits eIF4B (Figure 1). Formation of eIF4F complex is the
crucial molecular event that triggers translation initiation. The
formation of the eIF4F complex leads to the circularization of the
mRNA through the interaction between cap-eIF4E, eIF4G, and
poly A-binding proteins (PABP; Figure 1), which recruits ribo-
somes and promotes the unwinding of the secondary structure
of 5′UTR mRNA, thereby facilitating the recognition of the start
codon (Gingras et al., 1999; Klann and Dever, 2004). The eIF4F
complex is further regulated through phosphorylation of some of
its factors, such as eIF4G and eIF4E, which are phosphorylated
by mTORC1 and Mnk1/2, respectively (Figure 1). Currently, the
functional effect of the phosphorylation of eIF4G is not clear,
whereas phospho-eIF4E is thought to facilitate translation initia-
tion (Gingras et al., 1999; Pyronnet et al., 1999; Waskiewicz et al.,
1999; Raught et al., 2000).
ABERRANT mTORC1 ACTIVITY IS A COMMON MOLECULAR
PATHWAY FOR DISEASES OF CNS
Initially, the role of mTORC1 signaling in the physiology of the
nervous system was studied to understand the causal relationship
between mTOR-dependent translation and either brain synap-
tic plasticity or memory formation (Costa-Mattioli et al., 2009a;
Banko and Klann, 2008; Costa-Mattioli and Sonenberg, 2008).
The availability of speciﬁc pharmacological inhibitors of upstream
kinases, together with genetically modiﬁed mice that have dele-
tions in either upstream activators or downstream effectors have
greatly accelerated our understanding about the role of mTORC1
in nervous system function. In general, these studies have revealed
that mTORC1 critically modulates protein synthesis-dependent
synaptic plasticity and memory (Tang et al., 2002; Cammalleri
et al., 2003; Tischmeyer et al., 2003; Hou and Klann, 2004; Tsokas
et al., 2005; Dash et al., 2006; Gelinas et al., 2007; Antion et al.,
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2008a,b; Hoeffer et al., 2011). In addition, deletion of negative
regulators of mTORC1 results in aberrant synaptic plasticity and
altered memory function (Banko et al., 2005, 2006, 2007; Costa-
Mattioli et al., 2009b; Banko and Klann, 2008; Swiech et al., 2008;
Hoeffer and Klann, 2010). Thus, unbalanced mTORC1 signaling
that perturbs the precise regulation of protein synthesis appears
to be detrimental and have pathological consequences for ner-
vous system function. These ﬁndings are important in light of the
increasing amount of evidence linking dysregulated mTOR signal-
ing as a common molecular mechanism involved in the etiology
of several neurological disorders. In the next few sections we will
discuss recent studies implicating mTORC1-dependent protein
synthesis in disorders of the nervous system.
NEURODEVELOPMENTAL DISORDERS
Neurodevelopmental disorders are deﬁned as diseases caused by
abnormal development of the brain during the ﬁrst two decades of
life. These disorders have a strong and complex genetic basis with
diverse expression and thus, their clinical diagnosis is complicated
by a broad array of symptoms (Grice and Buxbaum, 2006; Per-
sico and Bourgeron, 2006; Levitt and Campbell, 2009). However,
it is possible to deﬁne a subgroup of these disorders that are char-
acterized by single-gene mutations and behavioral impairments
similar to those reported in autistic patients. Autism is diagnosed
based on the appearance of behavioral abnormalities that include
deﬁcits in social interaction skills, impaired ability to communi-
cate, and ritualistic-like repetitive behaviors (Hill and Frith, 2003).
A common molecular abnormality in several of these autism-like
disorders is loss-of-function mutations and/or deletion of genes
that encode proteins that normally repress mTORC1 signaling
pathway. These observations led to the hypothesis that dysregu-
lation of protein synthesis may be the cause of altered synaptic
development and plasticity, resulting in autistic-like phenotypes
in humans (Kelleher and Bear, 2008; Bourgeron, 2009; Hoeffer
and Klann, 2010).
Fragile X syndrome
Fragile X syndrome (FXS) is an X-linked form of metal impair-
ment caused by transcriptional silencing of the FMR1 gene. The
fragile X mental retardation protein (FMRP), encoded by the
FMR1 gene, is aRNA-binding protein that represses the translation
of speciﬁc mRNAs, such as MAP1B Arc/Arg3.1, αCaMKII, PSD-
95, SAPAP3 (Todd et al., 2003; Zalfa et al., 2003; Hou et al., 2006;
Muddashetty et al., 2007; Narayanan et al., 2008). Consistent with
this idea, ablation of FMRPhas been shown to increase the levels of
the proteins encoded by these speciﬁc mRNAs. Thus, the etiology
of FXS, resulting from the absence of functional FMRP, is an exag-
gerated synthesis of speciﬁc proteins. However, it also has been
shown that general protein synthesis is exaggerated in FXS model
mice (Qin et al., 2005; Dölen et al., 2007; Osterweil et al., 2010).
It has been proposed that the molecular mechanism mediating
FMRP-dependent repression of translation initiation is inhibition
of interactions of eIF4E and eIF4G (Figure 2). Indeed, FMRP
interacts with a non-canonical 4E-BP, named cytoplasmic FMRP
Interacting protein 1 (CYFIP1; Napoli et al., 2008). In addition,
it has been demonstrated that FXS model mice have exaggerated
mTORC1 signaling in the hippocampus resulting from increased
FIGURE 2 | Schematic of FMRP regulation of cap-dependent
translation initiation. FMRP represses the translation of speciﬁc mRNAs
via interaction with a 4E-BP-like protein termed CYFIP1, which also binds
eIF4E. One of the mRNAs regulated by FMRP is encoding for PIKE, which
enhances PI3K signaling. In fragile X syndrome (FXS), the absence of
functional FMRP results in the abnormal translation of PIKE and other
mRNAs. Indeed, in FXS model mice PI3K/mTORC1 signaling is enhanced.
Note that activation of surface receptors (i.e., group I mGluRs) promotes
PI3K signaling via PIKE and activation of mTORC1-dependent protein
synthesis. Activation of mTORC1 may also induce translation of
FMRP-dependent mRNAs via an unknown mechanism. Black solid arrows
indicate direct phosphorylation/activation, dashed arrows represent events
mediated by unknown molecular effectors.
expression of PIKE. Indeed, PIKE mRNAs are repressed by FMRP
and encode for aGTPase that enhances PI3K activity. Thus,PIKE is
abnormally synthesized in absence of FMRP resulting in enhanced
PI3K–Akt–mTORC1 signaling (Figure 2). These observations are
consistent with the idea that aberrant cap-dependent translation is
involved in FXS (Gross et al., 2010; Sharma et al., 2010). The mole-
cular abnormalities of FXSmodelmice are accompanied by several
behavioral deﬁcits, which include impairments in hippocampus-
dependent learning and memory in the Morris water maze and
terrestrial radial arm maze paradigms (Kooy et al., 1996; D’Hooge
et al., 1997; Mineur et al., 2002). In addition, FXS model mice
showed increased latency in ﬁnding the new platform position
in the reversal phase of the Morris water maze test, where the
position of the hidden platform is suddenly changed (D’Hooge
et al., 1997). This suggests that FXS model mice not only have
learning and memory deﬁcits, but also behavioral inﬂexibility in
switching to a new searching strategy. FXS model mice also exhibit
impaired contextual fear conditioning (Van Dam et al., 2000),
altered sensorimotor integration (Chen and Toth, 2001; Nielsen
et al., 2002), and increased susceptibility to audiogenic epileptic
seizures (Musumeci et al., 2000; Chen and Toth, 2001).
Tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dominant dis-
order caused by mutations in either hamartin (TSC1) or tuberin
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(TSC2),whichnegatively regulate themTORC1 signaling pathway,
and is clinically characterized by a high prevalence of autism and
cognitive impairments (Wiznitzer, 2004; Kwiatkowski and Man-
ning, 2005; Wullschleger et al., 2006). TSC1 is a chaperone protein
and TSC2 is a GTPase-activating protein (GAP) with catalytic
activity directed toward the small G protein Rheb (Inoki et al.,
2003). Loss-of-function mutations affecting TSC1/TSC2 result in
the abolishment of the GAP activity of TSC2 (Garami et al., 2003).
mTORC1 activation is typically regulated by TSC2 (Figure 1),
whichmediates the binding of GTP–Rheb (Ras homologs enriched
in the brain) to the mTORC1 kinase domain (Zhang et al., 2003).
Thus, TSC1/TSC2 mutations result in the exaggerated activation
of mTORC1 signaling pathway (Manning and Cantley, 2003a,b).
Mouse models utilized to study TSC have been engineered
with heterozygous mutations in the genes for either TSC1 or
TSC2. TCS model mice have been observed to display several
hippocampus-dependent learning and memory deﬁcits, includ-
ing impaired spatial learning and memory, and abnormalities
in contextual fear conditioning (Goorden et al., 2007; Ehninger
et al., 2008b) reminiscent of behavioral phenotypes displayed
by FXS model mice. In addition, TSC1 heterozygous knockout
mice and dominant/negative TSC2 mutant mice also displayed
impaired social behaviors (Goorden et al., 2007; Chevere-Torres
et al., 2012), whereas TSC2 heterozygous knockout mouse pups
exhibited abnormalities in social communication as demonstrated
by changes in ultrasonic vocalizations following maternal separa-
tion (Young et al., 2010). Together, these observations suggest that
mutation of only one of the two alleles encoding for the TSC
proteins is sufﬁcient to induce cognitive deﬁcits. Importantly, the
mTORC1 inhibitor rapamycin has been shown to be effective in
ameliorating learning and memory deﬁcits in TSC2 heterozygous
knockout mice (Ehninger et al., 2008b), suggesting that uncon-
trolledmTORC1 signaling is a coremolecularmechanism involved
in the behavioral abnormalities. Moreover, the TSC model mice
display behavioral abnormalities in the absence of neuropatho-
logical features such as brain tumors (tubers) and abnormalities
in neuronal spine density, which were assumed to be responsi-
ble for the cognitive deﬁcits displayed by TSC patients (Goorden
et al., 2007; Ehninger et al., 2008a; Chevere-Torres et al., 2012).
These ﬁndings imply that the pathological brain abnormalities in
TSC are not necessary for the occurrence of behavioral deﬁcits,
suggesting that their appearance results from the activity of other
molecular factors.
Mutation of phosphatase and tensin homolog on chromosome 10
Phosphatase and tensin homolog on chromosome 10 (PTEN) is
a tumor suppressor gene that is mutated in many human cancers
(Ali et al., 1999) as well as in brain disorders such as autism, men-
tal impairment, and macrocephaly (Zori et al., 1998; Gofﬁn et al.,
2001; Waite and Eng, 2002; Butler et al., 2005). PTEN has lipid
phosphatase activity and antagonizes the phosphatidylinositol
3-kinase (PI3K)-dependent signaling (Figure 1) by dephospho-
rylating the lipid targets of PI3K (Maehama and Dixon, 1999).
Thus, loss of PTEN function in neurons results in hyperactivation
of mTORC1, which is a downstream target of the PI3K/Akt sig-
naling pathway (Kwon et al., 2006a). Mice with genetic deletion
of PTEN restricted to a subset of differentiated hippocampal and
cortical neurons were shown to exhibit behavioral impairments
consistent with clinically relevant autistic behaviors. For exam-
ple, the conditional PTEN mutant mice exhibited abnormalities
in social behavior accompanied by deﬁcits in pre-pulse inhibition,
anxiety-like behaviors, and seizures (Kwon et al., 2006a,b). The
behavioral abnormalities of PTEN mutant mice were observed
in the absence of dramatic brain pathologies, which is similar to
what was observed in TSC heterozygous knockout mice (Kwon
et al., 2006a).
Phosphatase and tensin homolog on chromosome 10 mutant
mice have been shown to develop macrocephaly as well as abnor-
malities in dendritic arborization and axonal growth (Kwon et al.,
2006a). Importantly, pharmacological attenuation of mTORC1
activity with rapamycin reduced the impairments in social interac-
tions and the duration and frequency of spontaneous seizures as
well as neuronal hypertrophy responsible for the macrocephaly.
This suggests that exaggerated mTORC1 signaling pathway is
responsible for the behavioral abnormalities observed in PTEN
mutant mice (Zhou et al., 2009). Thus, these ﬁndings are consis-
tent with the notion that upregulated mTORC1 signaling results
in behavioral abnormalities in both TSC model mice and PTEN
mutant mice.
Deletion of FKBP12 gene
Genetic studies demonstrate that chromosomal deletions imme-
diately ﬂanking the gene encoding for FK506-binding protein
12 (FKBP12) are present in autistic patients (Sebat et al., 2007).
FKBP12 is an immunophilin that binds rapamycin and regulates
the phosphorylation of mTORC1 substrates by blocking the for-
mation of the mTORC1 complex (Jacinto and Hall, 2003). Thus,
genetic deletion of FKBP12 should result in exaggerated mTORC1
activity (Figure 1). The hypothesis that increased mTORC1 sig-
naling is involved in the onset of autism-like syndromes has been
tested with conditional knockout mice in which the FKBP12 gene
was removed in the forebrain at approximately 3weeks of age
(Hoeffer et al., 2008). Deletion of FKBP12 was associated with
increased activity of mTORC1 as shown by an augmented interac-
tion between mTOR and Raptor and enhanced phopshorylation
of the mTORC1 target S6K1 (Hoeffer et al., 2008). The changes
in mTORC1 signaling in the FKBP12 conditional knockout mice
were accompanied by cognitive abnormalities, including enhanced
associative contextual fear conditioning,preference for the familiar
object in the novel object recognition test, and behavioral inﬂexi-
bility in several reversal learning paradigms (Hoeffer et al., 2008).
These ﬁndings suggest that exaggerated mTORC1 activation leads
to multiple behavioral abnormalities, including increased perse-
veration. Furthermore, these results imply that autistic behav-
iors in syndromes with upregulated mTORC1 signaling are not
entirely predetermined during development because dysregula-




Depression is a neuropsychiatric disorder characterized by anhe-
donia, irritability, depressed mood, difﬁculties in concentrating,
and abnormalities in appetite and sleep (Krishnan and Nestler,
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2008). Complications in the current pharmacotherapy for depres-
sion are related mainly to the long duration of time required
by the treatment to produce a therapeutic response and the
abundance of treatment-resistant patients (Clark et al., 2009).
Clinical studies revealed that low doses of ketamine, a non-
selective NMDA receptor (NMDAR) antagonist, produces a rapid
and sustained antidepressant effects that are also observed in
patients with treatment-resistant depression (Berman et al., 2000;
Zarate et al., 2006; Price et al., 2009). Thus, NMDARs may play
an important role not only in the pathophysiology of depres-
sion, but also as a novel molecular target for the mechanism
of action of antidepressant drugs. However, the molecular con-
nection between antagonism of NMDARs and antidepressant
behavioral effects is unknown. Recently, two independent stud-
ies demonstrated that administration of a non-anesthetic dose of
ketamine produced antidepressant-like behavior in rodents but
the molecular mechanisms responsible for this effect appear to be
different.
Nanxin et al. (2010) showed that ketamine transiently acti-
vates mTORC1 signaling in the prefrontal cortex (PFC) of rats.
This treatment results in mTORC1-dependent synthesis of new
pre- and postsynaptic proteins, such as Arc, synapsin, PSD-95,
and GluR1, that are required for plastic changes at new spines
and synapses. Accordingly, the enhanced mTORC1-dependent
synthesis of synapse-associated proteins was accompanied by a
rapid increase in spine density and increased excitatory post-
synaptic currents (EPSCs) in layer V pyramidal neurons in the
PFC (Nanxin et al., 2010). Thus, acute ketamine administra-
tion results in enhanced mTORC1-dependent protein synthesis,
which leads to long-term changes in PFC neurons, such as an
increase in synapses and spine formation, and enhanced synaptic
strengthening. Importantly, intracerebroventricular (ICV) infu-
sion of rapamycin blocked all the physiological effects induced
by ketamine, which strongly suggests that the formation of new
spines and increases in synaptic strength and antidepressant-like
behaviorswere functional consequences of activationof mTORC1.
Furthermore, “depressed rats” exhibit reduced levels of GluR1,
PSD-95, and synapsin I in the PFC, and a single dose of ketamine
normalized the levels of these proteins in an mTORC1-dependent
manner (Nanxin et al., 2010). These results indicate that depres-
sion may be the pathophysiological consequence of altered spine
remodeling and synaptic plasticity in the PFC.
In contrast, Autry et al. (2011) demonstrated that the anti-
depressant effects of ketamine are mediated by the synthesis of
BDNF in the hippocampus. Indeed, increased BDNF expres-
sion was blocked by anisomycin, which is a general inhibitor of
protein synthesis. Reduction of BDNF levels in the hippocam-
pus also was accompanied by blockade of antidepressant-like
behavior. Furthermore, BDNF and neurotrophic tyrosine kinase
receptor type 2 (TrkB receptor) null mice were resistant to the
antidepressant effects of ketamine, strongly suggesting that newly
translated BDNF mediates the positive, antidepressant effects of
NMDA receptor blockade. The authors also demonstrated that
acute blockade of NMDA receptor decreased phosphorylation of
elongation factor 2 (eEF2), which normally promotes the riboso-
mal translocation of the nascent polypeptide chain. Phosphoryla-
tion of eEF2 inhibits its catalytic activity and blocks ribosomal
translocation, thereby halting ribosomes and blocking protein
synthesis. Mice pharmacologically treated with inhibitors of eEF2
phosphorylation showed antidepressant-like behavior accompa-
nied by increased BDNF levels in the hippocampus (Autry et al.,
2011). These ﬁndings suggest that reduction of eEF2 phospho-
rylation is sufﬁcient to disinhibit protein synthesis, stimulate
translation of BDNF, and promote antidepressant-like behaviors.
Thus, drugs targeting eEF2 kinase activity are a potential novel
pharmacological treatment for depression.
It appears that antidepressant drugs share the ability of increase
protein synthesis. Indeed, this is a common molecular mecha-
nism of drugs antagonizing NMDA receptors (ketamine; Nanxin
et al., 2010; Autry et al., 2011) as well as inhibiting the reuptake
of serotonin (ﬂuoxetine; Dagestad et al., 2006). Thus, one could
reasonably conclude that dysregulation of translational control
is a molecular mechanism involved in the onset of depressive
syndromes.
Schizophrenia
The involvement of mTORC1 signaling in schizophrenia has been
suggested by genetic and biochemical studies conducted in schiz-
ophrenic patients. Indeed,mutations of the Akt1 gene on chromo-
some 14q22–32 are associated with genetic form of schizophrenia
(Harrison, 1999). Diminished Akt expression and kinase activity
accompanied by reduced phosphorylation at Ser473 was found
in postmortem brains of patients with schizophrenia (Kalkman,
2006; Zhao et al., 2006). Moreover, decreased expression of the
catalytic subunit of PI3K was detected in lymphocytes of schizo-
phrenic individuals (Middleton et al., 2005). These studies suggest
that schizophrenia may be a consequence of decreased activity of
the PI3K–Akt signaling cascade. Accordingly, some antipsychotic
drugs result in the correction of dysfunctional PI3K–Akt signaling
pathway (Chalecka-Franaszek and Chuang, 1999; Lu and Dwyer,
2005; Kalkman, 2006). Both PI3K andAkt are upstream regulators
of mTORC1 (Kalkman, 2006), but whether mTORC1 is down-
regulated due to decreased activity of PI3K and/or Akt has not
been clearly demonstrated in schizophrenia. Recently, the con-
sequences of reduced Akt activity were investigated in a mouse
model in which phosphorylation of Ser473 was abrogated selec-
tively in neurons by genetic deletion of Rictor, the key regulatory
subunit of mTORC2 (Siuta et al., 2010). Mice that lack mTORC2-
dependent phosphorylation of Akt on Ser473 exhibited decreased
pre-pulse inhibition, consistent with impairments in sensorimo-
tor integration. These behavioral impairments were accompanied
by alterations in cortical catecholamine content, as evidenced by
decreased levels of dopamine (DA) and increased levels of nor-
epinephrine (NE) in the PFC (Siuta et al., 2010). This ﬁnding is
consistent with experimental models of schizophrenia that sug-
gest that dysregulation in cortical DA content contribute both to
cognitive deﬁcits and negative symptoms (Weinberger et al., 1988;
Davis et al., 1991; Howes and Kapur, 2009). The molecular link
between decreased mTORC2–Akt signaling and abnormalities in
DA levels in the PFC of Rictor null mice was explained by an Akt-
dependent increase in surface expression and function of the NE
transporter (NET), resulting in enhanced uptake of DA in nora-
drenergic neurons and its conversion to NE (Siuta et al., 2010).
Finally, administration of nisoxetine, a NET inhibitor, reversed
the sensorimotor deﬁcits and the DA content in the PFC of the
Rictor null mice, suggesting that the behavioral deﬁcits displayed
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by the mice are a consequence of an Akt-dependent imbalance in
cortical levels of DA (Siuta et al., 2010).
Other evidence of the critical involvement of Akt signaling
in schizophrenia comes from studies in which Akt activity is
increased. For example, suppression of DISC1 activity results
in increased phosphorylation of Akt and ribosomal protein S6,
which is a downstream effector of mTORC1, during adult neu-
rogenesis in the hippocampus (Kim et al., 2009). DISC1 is a gene
that was identiﬁed at the breakpoint of a chromosomal translo-
cation (Blackwood et al., 2001; Chubb et al., 2008). Disruption
of DISC1, due to genetic rearrangement, co-segregates with sev-
eral psychiatric disorders, including schizophrenia (Millar et al.,
2000; Blackwood et al., 2001). DISC1 regulates Akt by blocking
KIAA1212,which is a binding partner of Akt (Figure 1). Therefore,
deletion of DISC1 results in uncontrolled binding of KIAA1212
to Akt, leading to enhanced Akt signaling (Kim et al., 2009).
Genetic manipulations that increase Akt activity resemble the
defects caused by DISC1 suppression; importantly, these defects
were rescued by inhibition of mTORC1 activity with rapamycin
(Kim et al., 2009). These ﬁndings identiﬁed Akt–mTORC1 as a
critical downstream target of DISC1 in neuronal development. It
will be important to determine how these molecules, which have
been indicated as schizophrenia-related genes, can contribute to
the etiology of schizophrenia.
NEURODEGENERATIVE DISEASES
Parkinson’s disease
Parkinson’s disease is a progressive neurodegenerative disorder
that results from loss of the dopaminergic (DAergic) neurons
located in the substantia nigra pars compacta that project to
the striatum (nigrostriatal DAergic pathway). The loss of stri-
atal DA content leads to motor symptoms such as bradykinesia,
rigidity, and tremor (Parkinson, 2002). Recent studies address-
ing the mechanism of neurodegeneration in PD demonstrate the
involvement of the mTORC1 signaling pathway in the survival
mechanism of DAergic neurons.
In vivo and in vitro studies show that degeneration induced by
treatment with PD toxins, such as 6-OHDA and MPTP, leads to
upregulation of RTP801, a protein encoded by a RTP801 stress-
responsive gene, which in turn reduces mTOR kinase activity.
Importantly, enhanced RTP801 was also found in nigral DAergic
neurons of postmortem human PD brains. Accordingly, neurons
with inhibited expression of RTP801 or overexpression of mTOR
were protected from the insults induced by the toxins and showed
high survival rate (Malagelada et al., 2006). These studies sug-
gest that neurodegeneration induced by PD toxins is dependent
on upregulated RTP801 and the subsequent reduction of mTOR
signaling.
It has been proposed that the molecular mechanism, linking
high levels of RTP801 to mTORC1 inhibition and neurodegener-
ation involves TSC2 and Akt (Deyoung et al., 2008; Malagelada
et al., 2008; Figure 1). Either genetic manipulations that interfere
withTSC2or increase the expression of a constitutively active form
of Akt protected against the PD toxins and prevented the increase
in RTP801 (Malagelada et al., 2008). These ﬁndings suggest that
PD toxins induce neurodegeneration through inhibition of Akt,
elevation of RTP801 levels, and TSC1/2-dependent suppression of
mTORC1 activity. Importantly, DAergic neurons of PD patients
also exhibited diminished levels of Akt phosphorylation together
with increased expression of RTP801 (Malagelada et al., 2010).
Thus, treatments that inhibit mTORC1 signaling should lead to
an enhanced toxicity and even a greater DAergic loss. Surpris-
ingly, rapamycin was reported as neuroprotective agent both in
cell culture and in a MPTP mouse model. The beneﬁcial effect of
rapamycin, which inhibits mTORC1, has been explained through
selective maintenance of mTORC1-dependent activities responsi-
ble for neuronal survival whereas RTP801, which acts upstream
of mTORC1, would completely block all of its downstream phys-
iological effects (Malagelada et al., 2010). For example, inhibition
of mTORC1 may reduce the synthesis of new RTP801, thereby
relieving RTP801-dependent inhibition of mTORC1 and stimu-
lating the phosphorylation of the survival promoting kinase Akt
(Malagelada et al., 2010). Alternatively, rapamycin may enhance
Akt activity through inhibition of mTORC1-dependent activation
of S6K1 and the subsequent reduction of phospho-IRS-1, which is
a scaffold protein involved in the activation of PI3K andAkt (Shah
et al., 2004).
The mTORC1 signaling cascade also was shown to be involved
in the onset of levodopa-induced dyskinesia (LID), a debilitating
side effect associated with the pharmacotherapy of PD (San-
tini et al., 2009b). LID consists of dystonic and choreic motor
disturbances that are induced by repetitive and discontinuous
administration of l-DOPA, the main therapy of choice for the
treatment of PD (Bezard et al., 2001). A single administration of
l-DOPA induces transient activation of mTORC1 signaling in a
mouse model of PD (Santini et al., 2009b). Upregulated mTORC1
activity, measured by increased phosphorylation of downstream
effectors, occurred in the dopamine D1 receptor (D1R) express-
ing subset of striatal neurons, speciﬁcally medium spiny neurons
(MSNs), which were previously implicated as an important site
for the onset and development of LID (Gerfen et al., 2002; Westin
et al., 2007; Santini et al., 2008, 2009a; Darmopil et al., 2009).
Accordingly, the ability of l-DOPA to activate mTORC1 signaling
in D1R-bearing MSNs was maintained with repetitive adminis-
tration of the drug and was correlated with the severity of the
degree of dyskinesia. Treatment with rapamycin together with l-
DOPA relieved the dyskinetic side effects without reducing the
positive, anti-parkinsonian efﬁcacy of drug (Santini et al., 2009b).
These results suggest that inhibitors of mTORC1 may be used clin-
ically as antidyskinetic agents. In summary, rapamycin and other
inhibitors of mTORC1 have promising therapeutic potential for
the treatment of PD, both as neuroprotective and antidyskinetic
drugs.
Huntington’s disease
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by an expansion mutation of the trin-
ucleotide CAG in exon 1 of the huntingtin (HTT ) gene. The
expansion mutation is translated into an abnormally long polyg-
lutamine tract at the N terminus of huntingtin (MacDonald et al.,
1993). The pathogenic mechanism by which huntingtin with an
extended polyglutamine tract induces neuronal dysfunction and
neurodegeneration is not fully understood. However, mutated
huntingtin localizes in intraneuronal aggregates together with
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other aggregate-prone proteins, and these inclusions appear to
be deleterious for the neurons (Davies et al., 1997; Saudou et al.,
1998; Rubinsztein, 2002). Turnover of huntingtin was found to
be impaired after inhibition of the autophagy–lysosome path-
way (Ravikumar et al., 2002) suggesting that this pathway is
involved in the clearance of the intracellular inclusions. Acti-
vation of mTORC1 also inhibits autophagy (Figure 1) in cells
from yeast to humans (Schmelzle and Hall, 2000). Consistent
with this observation, induction of autophagy by inhibition of
mTORC1 with rapamycin resulted in protection against mutated
huntingtin-induced toxicity and enhanced clearance of aggre-
gates. In the same cell line, the ability of rapamycin to inhibit
mTORC1 and subsequently reduce inclusions was impaired after
prolonged expression of mutated huntingtin (Ravikumar et al.,
2002). The decreased effectiveness of rapamycin was explained
with the localization of mTOR in the intracellular inclusions after
prolonged expression of mutated huntingtin (Ravikumar et al.,
2004). Co-localization of mTOR and mutated huntingtin to the
inclusions was also described in the brain of transgenic mice
expressing mutant huntingtin and, most importantly, in human
patients affected by HD (Ravikumar et al., 2004). The interaction
between mTOR and mutated huntingtin also was conﬁrmed with
co-immunoprecipitation in cultured cells and in brain lysates from
mutant huntingtin transgenicmice (Ravikumar et al., 2004). Thus,
mTOR and mutated huntingtin are sequestered together in intra-
cellular inclusions, resulting in inactivation of mTORC1 as evi-
denced by reduced levels of phosphorylation of S6K1, 4E-BP2, and
S6 both in cell culture and in the brains of the mutant huntingtin
transgenic mice. In these conditions, mTORC1-dependent pro-
tein synthesis and autophagy were impaired and were not further
reduced by treatment with rapamycin (Ravikumar et al., 2004).
These ﬁndings suggest that inhibition of mTORC1 is effective in
preventing toxicity induced by mutant huntingtin only in ear-
lier stages of disease, possibly when mTOR is not yet sequestered
and inactivated in the intracellular inclusions. Consistent with
this idea, chronic administration of rapamycin to HD model mice
before disease onset rescued the behavioral deﬁcits associated with
the progression of the disease (Ravikumar et al., 2004). HD model
mice treated with rapamycin exhibited improvement in perfor-
mance in four different behavioral paradigms used to test motor
dysfunction: rotarod test, grip strength test, wire maneuver, and
presence of tremors (Ravikumar et al., 2004).Moreover, the behav-
ioral recovery in these mice was accompanied by a reduction in
the number and size of striatal and cortical inclusions (Ravikumar
et al., 2004). Taken together, these ﬁndings suggest that early phar-
macological intervention to inhibit mTORC1 signaling effectively
reduces neurological phenotypes in animal models of HD.
Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by the formation of
amyloid plaques and neuroﬁbrillary tangles (NFTs), which are
correlated with neurodegeneration in brain areas implicated in
acquisition and storage of declarative memory, such as the hip-
pocampus, entorhinal cortex, amygdala, and associative regions of
the cortex (Nestor et al., 2006; Götz and Ittner, 2008). The major
component of plaques is the polypeptide Aβ that is derived from
the amyloid precursor protein (APP),whereas NFTs are composed
of hyperphosphorylated forms of the microtubule-associated pro-
tein tau (Glenner and Wong, 1984; Kang et al., 1987; Tanzi et al.,
1987; Binder et al., 2005).
Studies on the regulation of the mTORC1 signaling pathway
in AD has revealed a complicated picture, mainly due to the
lack of agreement about the direction of mTORC1 dysfunction
(increase vs. decrease) and the pathogenic mechanism leading
to neurodegeneration (Swiech et al., 2008). Aβ and tau exert
toxicity through distinct mechanisms but there is now evidence
from human, rodent, and in vitro studies demonstrating a link
between Aβ and tau in neurotoxicity, although the molecular
nature of this link remains elusive (Ittner and Götz, 2011). Stud-
ies of Aβ-induced neurotoxicity report increased phosphorylation
of double-stranded RNA-dependent protein kinase (PKR; Chang
et al., 2002a,b; Peel andBredesen, 2003;Onuki et al., 2004), eukary-
otic initiation factor 2α (eIF2α; Chang et al., 2002a,b) and S6K1
(An et al., 2003) in mouse models of AD and AD patients. For
example, the Aβ peptide is shown to activate PKR and Aβ-induced
neurotoxicity was reduced in neuronal cultures from PKR knock-
out mice. (Chang et al., 2002b) Furthermore, increased levels
of phosphorylated PKR were found in APP/PS1 mutant mice, a
rodent model of AD expressing human APP with the Swedish
and London mutation, as well as presenilin 1 (PS1) carrying
two different mutations known to cause a familial, early onset
form of the disease (Page et al., 2006). These studies suggest a
correlation between Aβ-induced neurotoxicity and a decrease in
translation, as PKR attenuates protein synthesis through eIF2α
phosphorylation. In support of the idea that AD is accompanied
by reduction of protein translation, the mTORC1 signaling cas-
cade was found to be impaired in a mouse model of AD and was
correlated with impaired synaptic plasticity (Ma et al., 2010). It
was possible to mimic these impairments by treating hippocampal
slices of wild-type mice with soluble Aβ. Importantly, pharmaco-
logical and genetic manipulation leading to increased mTORC1
signaling restored the synaptic plasticity deﬁcits of the AD model
mice and prevented Aβ-induced impairments in synaptic plas-
ticity in wild-type mice (Ma et al., 2010). Altogether, these data
indicate that there is an association between Aβ-induced toxic-
ity, enhanced eIF2α phosphorylation, and deﬁcits in mTORC1
signaling pathway.
On the other hand, several groups have reported increases
in the phosphorylation of S6K1, mTOR, eIF4E, and 4E-BP2 in
AD brains (Li et al., 2004, 2005). This led to the hypothesis
that enhanced mTORC1 signaling could be responsible for the
high levels of toxic proteins such as tau (Pei et al., 2008). In
addition, hyperactivated mTORC1 signaling was also positively
correlated with the levels of total and phosphorylated tau. Thus,
the continuous synthesis of tau in degenerating neurons could
be the result of upregulated mTORC1 signaling (Pei and Hugon,
2008). Furthermore, increased levels of phosphorylated mTOR
and S6K1 were also found in some of the brain areas affected
in AD, such as cortex, in the same double APP/PS1 transgenic
mice (Lafay-Chebassier et al., 2005). Importantly, chronic treat-
ment with rapamycin rescued learning and memory deﬁcits in
two different mouse models of AD (Caccamo et al., 2010; Spilman
et al., 2010) suggesting that enhancedmTORC1 activity is involved
in the cognitive impairments.
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PSYCHOACTIVE DRUGS
The use of the term psychoactive when describing drugs refers
to a diverse group of chemicals that act primarily at the level of
the central nervous system and affect brain function, resulting
in changes of mood, cognition, perception, and consciousness.
These substances are often used recreationally even if originally
synthesized for the therapeutic use, namely to treat both physi-
cal and neuropsychiatric disorders (Di Chiara and North, 1992;
Nestler, 2004). Recently, studies have demonstrated that discrete
behavioral effects induced by some of these drugs are caused by
activation of the mTORC1 signaling pathway in the brain.
Cannabinoids
Cannabis sativa is included in marijuana, hashish, bhang, and
other well-known illicit psychoactive drugs that are largely used
recreationally (Pierce and Kumaresan, 2006). The primary psy-
choactive ingredient of cannabis is Δ9-tetrahydrocannabinol
(THC; Gaoni and Mechoulam, 1964), which is responsible for
multiple behavioral effects including euphoria, enhanced sensory
perception, increased appetite, analgesia, memory impairment,
anxiety, paranoia and, at higher doses, sedation (Ameri, 1999;
Piomelli, 2003; Pierce andKumaresan,2006). Experimentalmouse
models are utilized to study behaviors induced by THC (Hamp-
son and Deadwyler, 1999; Maldonado and Rodriguez De Fonseca,
2002). For example, acute administration of THC to mice imme-
diately after training in the novel object recognition task produced
impairment in long-term memory, as indicated by the inability
of THC-treated mice to discriminate between familiar and novel
objects (Puighermanal et al., 2009). Moreover, the same dose of
THC activated the mTORC1 signaling cascade in the hippocam-
pus, as indicated by increased phosphorylation of downstream
targets, such as S6K1,S6, eIF4E, eIF4G,and 4E-BP2 (Puighermanal
et al., 2009). The behavioral and molecular changes induced by
THC were abolished in CB1 receptor knockout mice and in mice
with a conditional deletion of the CB1 receptor in GABAergic
neurons. Moreover, pretreatment of mice with either rapamycin
or anisomycin abolished the amnesic-like effects induced by THC,
suggesting that thememory impairment ismediated bymTORC1-
dependent translation (Puighermanal et al., 2009). Surprisingly,
the THC-induced activation of the mTORC1 cascade was local-
ized in glutamatergic pyramidal neurons and was dependent on
NMDA receptors (Puighermanal et al., 2009). This indicates that
the amnesiac-like effect induced by THC is most likely mediated
via a heterosynaptic mechanism because CB1 and NMDA recep-
tors are localized in different hippocampal neurons (GABAergic
basket-cells and glutamatergic pyramidal neurons, respectively).
It is also interesting to note that the same molecular process of
protein translation occurring in hippocampal pyramidal neurons,
is involved in opposing behavioral processes; memory consolida-
tion vs. THC-induced memory loss. A possible explanation for the
contradictory functional effects of translation may be due to the
different synaptic locations where it occurs (Mackie and Katona,
2009). Indeed, in pyramidal neurons THC-induced activation of
mTORC1, and potentially translation, occurs in the stratum pyra-
midale, a cellular regionwith a highdensity of GABAergic synapses
(Papp et al., 2001). Thus, it is possible that enhanced translation in
the soma of pyramidal neurons results in memory impairments,
whereas enhanced translation in dendritic spines at excitatory
synapses is required for memory formation (Costa-Mattioli et al.,
2009b; Richter and Klann, 2009).
Cocaine
Cocaine recently was shown to activate the mTORC1 signaling
cascade in brain regions that undergo long-lasting neuroadap-
tation in response to drug exposure, including the mesolimbic
dopamine pathway (VTA) and its forebrain targets, especially the
nucleus accumbens (NAc; Nestler, 2005; Mameli et al., 2007;Wang
et al., 2010; Wu et al., 2011). Speciﬁcally, systemic administration
of cocaine in mice increased the phosphorylation of the mTORC1
downstream effector S6 in theVTA andNAc (Wu et al., 2011). Sen-
sitization to cocaine is often measured in behavioral experiments
as an increase in locomotor activity. Behavioral sensitization con-
sists of an initial induction phase, in which repeated injections of
cocaine leads to an increase in locomotor activity. Induction is fol-
lowed by drug withdrawal and then re-exposure to the drug for the
expression phase of sensitization, which results in an even greater
enhancement in locomotor activation (Berridge and Robinson,
1998). Rapamycin effectively reduced both induction and expres-
sion of cocaine-induced locomotor sensitization (Wu et al., 2011),
suggesting that mTORC1 signaling may underlie the different
adaptive changes elicited by cocaine exposure during induction
and expression phases of locomotor sensitization. Notably, it also
has been shown that cocaine induces altered synaptic plasticity in
DA neurons of the VTA in an mTORC1- and protein synthesis-
dependent manner (Mameli et al., 2007). These ﬁndings provide
additional evidence for cocaine-induced activation of mTORC1.
Another aspect of cocaine addiction linked to activation of
mTORC1 signaling is relapse, which is experienced by addicts
after a prolonged period of abstinence and induced by craving-
provoking environmental cues paired with the rewarding prop-
erties of the drug (Gawin and Kleber, 1986a,b; O’Brien, 1997;
Childress et al., 1999; Wang et al., 2010). Cue-induced relapse is
modeled in rodents with a reinstatement paradigm, in which rats
are trained to self-administer a drug reward paired with a discrete
cue. Lever pressing is then extinguished in the absence of the dis-
crete cue. During a reinstatement test, exposure to the discrete cue
reinstates drug-seeking behavior as measured by increased lever
pressing (Meil and See, 1997; Kruzich and See, 2001). Reinstate-
ment of drug-seeking behavior in rats exposed to a cue previ-
ously associated with the drug was accompanied by an increase
of mTORC1 activation in the NAc, as measured by increased
phosphorylation of S6K1 and S6 (Wang et al., 2010). Infusion
of rapamycin in the NAc core before the reinstatement test signif-
icantly decreased the cue-induced seeking behavior (Wang et al.,
2010). These behavioral effects are NMDA-dependent as NMDA
agonist infusions into the NAc core enhanced the reinstatement
of cue-induced cocaine seeking by increasing the activation of the
mTORC1cascade,and co-infusions of rapamycinblockedboth the
molecular and behavioral effects (Wang et al., 2010). These ﬁnd-
ings suggest thatmTORC1-dependent protein synthesis in theNAc
core is involved in reinstatement of cue-induced seeking behavior.
Because rapamycin administered acutely before the reinstatement
test reduces the cue-induced cocaine seeking, it could used ther-
apeutically to treat relapse in cocaine addicts (Wang et al., 2010).
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Importantly, it has been shown that rapamycin reduced the crav-
ing induced by a drug-related cue in abstinent heroin addicts (Shi
et al., 2009).
CONCLUSION AND FUTURE DIRECTIONS
It is clear that mTORC1 is a critical regulator of multiple func-
tions of the central nervous system. In this review, we have
described a series of disorders in which there is a clear association
between neuropathology and regulation of mTORC1-dependent
translation (see Table 1 for a summary).
However, mTORC1 has several other physiological functions
that either are not fully understood or have not yet been explored.
For instance, the role of dysregulated mTORC1 signaling in
autophagy in neurons, and its association with diseases has the
potential to open a completely new line of research. Furthermore,
there are aspects of cap-dependent protein synthesis that are reg-
ulated via mTORC1 that deserve more attention and/or need to
be addressed in more detail. For example, the molecular machin-
ery that is involved in the sorting and localization of particular
mRNAs at speciﬁc neuronal subregions is poorly understood, as
is the identity of the mRNAs whose translation is regulated by
mTORC1.
An open question that needs to be addressed in greater detail is
the role that mTORC1 plays in the pathophysiology of the CNS.
Table 1 | Summary of altered mTORC1 signaling in brain disorders and in response to psychoactive drugs.












Not examined Sharma et al. (2010)
Tuberous sclerosis
complex
↑ p-S6 Hippocampus Rescue of deﬁcits in spatial
memory (Morris water maze)
and context discrimination
Ehninger et al. (2008a)
PTEN mutation
(autism)
↑ p-S6 Hippocampus Rescue of impaired social
behaviors, seizures, and
macrocephaly





Prefrontal cortex Blockade of antidepressant
effects of ketamine (forced
swim and novelty suppressed
feeding tests)
Nanxin et al. (2010)
Schizophrenia ↑ p-S6 Hippocampus Not examined Kim et al. (2009)
Parkinson’s disease ↓ in PD p-S6K1, p-S6,
p-4E-BP, and p-eIF4E
Striatum Reduction of l-DOPA-induced
dyskinesia
Malagelada et al. (2006),
Santini et al. (2009b)
↑ in l-DOPA-induced
dyskinesia





in rotarod, grip, and wire
tests; reduction of tremor
Ravikumar et al. (2004)





Rescue of spatial memory
(Morris water maze)
An et al. (2003), Li et al.
(2004), Lafay-Chebassier
et al. (2005), Caccamo
et al. (2010), Spilman et al.
(2010)
Cannabis (THC) ↑ p-S6K1, p-S6,
p-eIF4E, p-eIF4G,
p-4E-BP
Hippocampus Blockade of amnesic-like
effects of THC (novel object
recognition and context
discrimination tests)
Puighermanal et al. (2009)







Wu et al. (2011),Wang
et al. (2010)
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The ubiquitous distribution and the ﬁne control of mTORC1 sig-
naling render it difﬁcult to ascertainwhethermTORC1 is the cause
and/or one of the consequences of various brain disorders dis-
cussed in this review. At minimum, we would argue in favor of a
causative role of mTORC1 in the etiology of brain disorders where
behavioral abnormalities are corrected either by pharmacological
or genetic manipulations of mTORC1.
Most research investigating mTOR signaling in the brain is
focused on mTORC1, with very little known about mTORC2.
The contribution of mTORC2 to the functions of the central
nervous system needs to be clariﬁed. Moreover, since mTOR is
a component of both mTORC1 and mTORC2, there may be a
dynamic equilibrium regarding the relative amount of mTOR
engaged in the two mTORCs. Furthermore, it will be important
to understand whether there is interplay between mTORC1 and
mTORC2 during normal physiological processes in the brain,
in neurological disorders and/or in response to psychoactive
drugs.
Finally, the mTORC1 signaling pathway and its impact on pro-
tein synthesis is well characterized in some brain regions and cell
types such as glutamatergic pyramidal neurons of the hippocam-
pus, but it has not been rigorously explored in other regions. For
example,mechanisms of translational control in striatal GABArgic
neurons and/or glial cells have not been studied intensely. Thus, in
the future,more thorough studies of the mechanisms that regulate
translation will be necessary in diverse brain regions and cell types
in order to acquire a better understanding of how proteins are
synthesized throughout the brain in response to diverse stimuli.
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